H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Genmab to $46 from $51 and keeps a Buy rating on the shares following the 2022 results. The analyst is taking higher operating expenses into account but sees multiple catalysts for the shares in 2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GMAB:
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Transactions in connection with share buy-back program
- Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
- Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
- Notice to Convene the Annual General Meeting of Genmab A/S
